News Image

Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).

By Mill Chart

Last update: Jan 16, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ALKERMES PLC (NASDAQ:ALKS) is suited for growth investing. Investors should of course do their own research, but we spotted ALKERMES PLC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Exploring Why NASDAQ:ALKS Holds Promise for Growth Investors.

  • The Return on Equity(ROE) of ALKERMES PLC is 15.85%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
  • ALKERMES PLC has a strong history of beating EPS estimates in the last 4 quarters, signaling its ability to consistently exceed market expectations. This indicates the company's strong financial performance and its potential for creating shareholder value.
  • With impressive 1-year revenue growth of 40.56%, ALKERMES PLC showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
  • The q2q revenue growth of 50.91% of ALKERMES PLC highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
  • With a favorable trend in its operating margin over the past year, ALKERMES PLC demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
  • With a favorable trend in its free cash flow (FCF) over the past year, ALKERMES PLC demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
  • With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), ALKERMES PLC highlights its ability to generate increasing profitability, showcasing a 3.0K% growth.
  • The average next Quarter EPS Estimate by analysts was adjusted by 7.33%, reflecting the evolving market expectations for the company's EPS growth.
  • The recent financial report of ALKERMES PLC demonstrates a 3.0K% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
  • accelerating EPS growth for ALKERMES PLC: the current Q2Q growth of 3.0K% exceeds the previous year Q2Q growth of -85.71%.

Fundamental analysis of NASDAQ:ALKS

ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.

Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 602 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALKS get a neutral evaluation. Nothing too spectacular is happening here. ALKS is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make ALKS a good candidate for value and growth investing.

Check the latest full fundamental report of ALKS for a complete fundamental analysis.

More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

ALKERMES PLC

NASDAQ:ALKS (4/23/2024, 10:39:46 AM)

24.56

+0.49 (+2.04%)

ALKS News

News Image4 days ago - Market News VideoFirst Week of June 21st Options Trading For Alkermes (ALKS)
News Image6 days ago - Alkermes plcAlkermes to Report First Quarter Financial Results on May 1, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...

News Image6 days ago - ChartmillInvestors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.

Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.

News Image12 days ago - Market News VideoOversold Conditions For Alkermes (ALKS)
News Image13 days ago - ChartmillExploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).

ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.

News Image15 days ago - Alkermes plcAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...

News Imagea month ago - Market News VideoNoteworthy Tuesday Option Activity: ALKS, DKNG, VRT
News Imagea month ago - Market News VideoFirst Week of ALKS November 15th Options Trading
News Image2 months ago - Alkermes plcAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...

News Image2 months ago - Investor's Business DailyAmicus Therapeutics Stock Sees RS Rating Improve To 74

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

News Image2 months ago - Investor's Business DailyBeam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

News Image2 months ago - Investor's Business DailyAgios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark

Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

ALKS Links
Follow us for more